| You are here: Home: BCU 5|2004: Hyman B Muss, MD: Select publications
Select publications
Ahn Sr, JH et al. Phase II study of combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: Preliminary results. Proc ASCO 2002;Abstract 2030.
Domenech G et al. Vinorelbine/capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC). Proc ASCO 2001;Abstract 1939.
Ghosn M et al. Final results of a phase II study of vinorelbine in combination with capecitabine as first line chemotherapy for metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 270.
Gligorov J et al. Capecitabine and oral vinorelbine in metastatic breast cancer: Preliminary experience. Proc ASCO 2003;Abstract 351.
Hess DD et al. Phase I-II trial of capecitabine and vinorelbine in elderly patients (pts: > 65y) with metastatic breast cancer (MBC): SAKK 25/99 for the Swiss Group of Clinical Cancer Research, Berne, Switzerland. Proc ASCO 2002;Abstract 2915.
Lu Z et al. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998;4(2):325-9. Abstract
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Stuart N et al. Vinorelbine and capecitabine (VX) for advanced breast cancer — a phase II study showing good activity and potential for further development. Proc ASCO 2003;Abstract 183.
|
